FGEN FibroGen, Inc. Stock Quote

FGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-2.62	Insider Own	1.00%	Shs Outstand	90.56M	Perf Week	-3.90%
Market Cap	4.58B	Forward P/E	-	EPS next Y	-0.82	Insider Trans	-6.33%	Shs Float	83.64M	Perf Month	1.50%
Income	-228.80M	PEG	-	EPS next Q	-0.24	Inst Own	80.30%	Short Float	7.53%	Perf Quarter	21.05%
Sales	119.30M	P/S	38.38	EPS this Y	13.60%	Inst Trans	4.54%	Short Ratio	8.83	Perf Half Y	20.47%
Book/sh	4.99	P/B	10.03	EPS next Y	51.80%	ROA	-27.70%	Target Price	62.33	Perf Year	23.35%
Cash/sh	7.52	P/C	6.66	EPS next 5Y	-	ROE	-50.20%	52W Range	22.65 - 57.21	Perf YTD	34.89%
Dividend	-	P/FCF	113.06	EPS past 5Y	22.50%	ROI	-15.30%	52W High	-12.55%	Beta	1.36
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	13.30%	Gross Margin	94.00%	52W Low	120.88%	ATR	2.45
Employees	531	Current Ratio	6.20	Sales Q/Q	32.50%	Oper. Margin	-	RSI (14)	50.16	Volatility	5.41% 4.77%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	162.00%	Profit Margin	-	Rel Volume	0.91	Prev Close	49.86
Shortable	Yes	LT Debt/Eq	0.10	Earnings	Mar 01 AMC	Payout	-	Avg Volume	713.33K	Price	50.03
Recom	2.20	SMA20	-3.30%	SMA50	9.34%	SMA200	17.54%	Volume	646,967	Change	0.34%

Feb-01-21

Initiated

H.C. Wainwright

Buy

$58

Oct-26-20

Initiated

Raymond James

Underperform

Jul-10-20

Resumed

Stifel

Buy

$71

May-01-20

Initiated

Cowen

Market Perform

$40

Apr-27-20

Initiated

BofA/Merrill

Neutral

$45

May-29-19

Resumed

Goldman

Neutral

May-10-19

Downgrade

William Blair

Outperform → Mkt Perform

Apr-12-19

Initiated

Piper Jaffray

Neutral

$65

Feb-11-19

Resumed

Stifel

Buy

$71

Dec-19-18

Upgrade

Citigroup

Neutral → Buy

Aug-08-17

Reiterated

Stifel

Buy

$38 → $80

Aug-08-17

Reiterated

Leerink Partners

Outperform

$52 → $82

Jul-21-17

Downgrade

Goldman

Buy → Neutral

Jul-11-17

Initiated

Jefferies

Buy

Feb-11-16

Upgrade

Credit Suisse

Neutral → Outperform

$40

Jan-21-16

Initiated

Credit Suisse

Neutral

Dec-04-15

Initiated

Citigroup

Buy

Sep-23-15

Initiated

Lake Street

Hold

$25

Jul-29-15

Initiated

Citigroup

Buy

$37

Jul-20-15

Upgrade

Goldman

Neutral → Buy

Feb-21-21 02:52AM	Could The FibroGen, Inc. (NASDAQ:FGEN) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-18-21 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Feb-12-21 07:00AM	FibroGen to Present at Upcoming Investor Conferences GlobeNewswire
Dec-23-20 01:16AM	Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? Simply Wall St.
Dec-22-20 07:00AM	FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 GlobeNewswire
Dec-21-20 06:46PM	Why FibroGen Got Mashed on Monday Motley Fool -9.01%
Dec-18-20 04:59PM	FibroGen Provides Regulatory Update on Roxadustat GlobeNewswire
Dec-02-20 07:00AM	FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-20 08:00AM	FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer GlobeNewswire
Nov-30-20 01:39PM	FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication Zacks
Nov-29-20 07:03AM	FibroGen Gains Japanese Approval for Roxadustat; Mizuho Securities Sees 79% Upside TipRanks
Nov-27-20 07:00AM	Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis GlobeNewswire
02:02AM	Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire
Nov-08-20 07:46AM	FibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates Simply Wall St.
Nov-06-20 03:30PM	FibroGen Inc (FGEN) Q3 2020 Earnings Call Transcript Motley Fool
07:00AM	FibroGen to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-20 06:15PM	FibroGen (FGEN) Q3 Earnings Beat Estimates Zacks
04:01PM	FibroGen Reports Third Quarter 2020 Financial Results GlobeNewswire
03:30PM	FibroGen, Inc. to Host Earnings Call ACCESSWIRE
Nov-03-20 08:31AM	Cramer Gives His Opinion On Jumia Technologies, Nio, More Benzinga
Oct-30-20 09:02AM	Does FibroGen's (NASDAQ:FGEN) Share Price Gain of 53% Match Its Business Performance? Simply Wall St.
Oct-29-20 07:00AM	FibroGen to Report Third Quarter 2020 Financial Results GlobeNewswire
Oct-22-20 10:08AM	FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD) GlobeNewswire
Oct-14-20 07:00AM	FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined GlobeNewswire
Oct-02-20 07:00AM	New Ventures Funds Rebrands as Scientia Ventures PR Newswire
Sep-29-20 05:22PM	Hedge Funds Have Never Been More Bullish On FibroGen Inc (FGEN) Insider Monkey
Sep-15-20 07:31AM	Market Sentiment Around Loss-Making FibroGen, Inc. (NASDAQ:FGEN) Simply Wall St.
Sep-08-20 07:00AM	FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer GlobeNewswire
Sep-04-20 07:28AM	The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study Benzinga
Sep-01-20 07:00AM	FibroGen to Present at Upcoming Investor Conferences GlobeNewswire
Aug-11-20 07:00AM	FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy GlobeNewswire
Aug-06-20 08:10PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	FibroGen Reports Second Quarter 2020 Financial Results GlobeNewswire
04:01PM	FibroGen Announces New Appointments to its Board of Directors GlobeNewswire
Jul-30-20 12:33PM	Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline Zacks
Jul-24-20 09:35AM	What Type Of Shareholders Make Up FibroGen, Inc.'s (NASDAQ:FGEN) Share Registry? Simply Wall St.
Jul-23-20 07:00AM	FibroGen to Report Second Quarter 2020 Financial Results GlobeNewswire
Jul-17-20 03:31PM	Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ? Insider Monkey
Jun-24-20 12:00PM	FibroGen Begins Phase II Study for Acute Coronavirus in US Zacks
Jun-23-20 04:05PM	Sarepta Addressing Gene Therapy Issue With Two Acquisitions GuruFocus.com
07:00AM	FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 GlobeNewswire
Jun-22-20 07:00AM	FibroGen Appoints Thane Wettig as Chief Commercial Officer GlobeNewswire +5.78%
Jun-16-20 09:20AM	Hedge Funds Are Nibbling On FibroGen Inc (FGEN) Insider Monkey
Jun-15-20 10:42AM	Weekly CEO Buys Highlight: Camping World, FibroGen GuruFocus.com
Jun-10-20 08:37PM	FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher Zacks
Jun-09-20 10:17AM	FibroGen Initiates Phase II/III Study in Severe Coronavirus Zacks +6.49%
Jun-08-20 05:00PM	FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress GlobeNewswire
07:00AM	FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19 GlobeNewswire
May-27-20 07:00AM	FibroGen to Present at Upcoming Investor Conferences GlobeNewswire
May-21-20 07:00AM	European Medicines Agency Accepts Astellas Marketing Authorization Application for Roxadustat GlobeNewswire
May-20-20 10:00PM	European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat PR Newswire +6.07%
May-11-20 06:32AM	FibroGen, Inc. (NASDAQ:FGEN) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St. +8.76%
May-09-20 05:01PM	FibroGen Inc (FGEN) Q1 2020 Earnings Call Transcript Motley Fool
01:42AM	Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 07:00AM	FibroGen to Present at Bank of America Securities 2020 Health Care Conference GlobeNewswire
May-07-20 08:40PM	FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	FibroGen Reports First Quarter 2020 Financial Results GlobeNewswire
11:24AM	Akebia Shares Climb on Positive Anemia Drug Study Results GuruFocus.com
May-06-20 08:43AM	Why FibroGen (FGEN) Might Surprise This Earnings Season Zacks
May-03-20 10:17AM	How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Apr-30-20 12:33PM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks -7.22%
Apr-24-20 07:00AM	FibroGen To Report First Quarter 2020 Financial Results GlobeNewswire
Apr-21-20 05:31PM	Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO GuruFocus.com
Apr-20-20 07:00AM	FibroGen Reports UK Court Ruling GlobeNewswire
Mar-27-20 02:52PM	Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus Insider Monkey
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +12.38%
Mar-04-20 07:07AM	Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results Simply Wall St. +6.21%
Mar-03-20 08:13PM	Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT Thomson Reuters StreetEvents -8.55%
05:50PM	After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push American City Business Journals
Mar-02-20 05:15PM	FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-24-20 12:30PM	Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-12-20 09:45AM	FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA Zacks
09:18AM	The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 05:00PM	FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease GlobeNewswire
08:00AM	FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-03-20 03:42PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
Jan-31-20 09:12AM	FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Jan-30-20 12:01AM	Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan PR Newswire
Jan-13-20 05:59PM	2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc (FGEN) Insider Monkey
Jan-06-20 06:03PM	Four months after CEO's death, biotech company names Lilly vet as leader American City Business Journals
07:00AM	FibroGen Names Enrique Conterno as Chief Executive Officer GlobeNewswire
Dec-24-19 08:55AM	Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock? Zacks
Dec-23-19 05:42PM	Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests American City Business Journals
07:00AM	FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease GlobeNewswire
Dec-17-19 06:45AM	Is FibroGen's (NASDAQ:FGEN) 136% Share Price Increase Well Justified? Simply Wall St.
Dec-06-19 10:03AM	Hedge Funds Have Never Been This Bullish On FibroGen Inc (FGEN) Insider Monkey
Dec-02-19 07:00AM	FibroGen Announces Roxadustat Inclusion in Chinas National Reimbursement Drug List GlobeNewswire
Nov-15-19 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE +5.75%
Nov-14-19 07:42PM	FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
05:24PM	Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-13-19 08:03PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
07:00PM	Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
06:19PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
02:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
Nov-11-19 05:15PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks -14.94%
05:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
04:01PM	FibroGen Reports Third Quarter 2019 Financial Results GlobeNewswire
09:21AM	FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurkijarvi Kalevi	Director	Feb 17	Option Exercise	28.65	6,000	171,900	39,100	Feb 19 07:10 PM
Kurkijarvi Kalevi	Director	Feb 17	Sale	52.40	6,000	314,383	33,100	Feb 19 07:10 PM
Kurkijarvi Kalevi	Director	Jan 19	Option Exercise	19.05	6,000	114,300	39,100	Jan 21 07:24 PM
Kurkijarvi Kalevi	Director	Jan 19	Sale	43.38	6,000	260,280	33,100	Jan 21 07:24 PM
Kurkijarvi Kalevi	Director	Jan 14	Option Exercise	19.05	5,999	114,281	39,099	Jan 15 08:02 PM
Kurkijarvi Kalevi	Director	Jan 14	Sale	40.04	5,999	240,200	33,100	Jan 15 08:02 PM
Schoeneck James A	Director	Jan 04	Option Exercise	9.78	6,000	58,650	15,400	Jan 06 07:08 PM
Kurkijarvi Kalevi	Director	Dec 28	Option Exercise	18.34	6,001	110,059	39,101	Dec 30 06:07 PM
Kurkijarvi Kalevi	Director	Dec 28	Sale	40.40	6,001	242,455	33,100	Dec 30 06:07 PM
Yu K Peony	Chief Medical Officer	Dec 16	Sale	41.61	3,350	139,394	192,292	Dec 17 07:06 PM
Cotroneo Pat	SVP, Finance and CFO	Dec 15	Sale	43.60	3,068	133,765	266,144	Dec 17 07:04 PM
Kouchakji Elias	SVP, Clinical Dev, Drug Safety	Nov 17	Option Exercise	14.58	7,082	103,220	134,495	Nov 19 04:52 PM
Yu K Peony	Chief Medical Officer	Sep 16	Sale	44.01	3,351	147,478	198,934	Sep 18 05:19 PM
Cotroneo Pat	SVP, Finance and CFO	Sep 15	Sale	43.63	3,070	133,944	272,226	Sep 17 06:03 PM
Yu K Peony	Chief Medical Officer	Sep 03	Option Exercise	18.00	10,000	180,000	215,576	Sep 04 04:33 PM
Cotroneo Pat	SVP, Finance and CFO	Sep 03	Option Exercise	23.30	15,004	349,582	293,314	Sep 04 04:30 PM
Yu K Peony	Chief Medical Officer	Sep 03	Sale	50.89	10,000	508,900	205,576	Sep 04 04:33 PM
Cotroneo Pat	SVP, Finance and CFO	Sep 03	Sale	50.91	15,004	763,854	278,310	Sep 04 04:30 PM
Schoeneck James A	Director	Aug 20	Option Exercise	5.95	6,000	35,700	15,400	Aug 21 05:58 PM
Cotroneo Pat	SVP, Finance and CFO	Aug 11	Option Exercise	18.72	7,250	135,713	278,310	Aug 11 04:34 PM
Cotroneo Pat	SVP, Finance and CFO	Aug 07	Option Exercise	19.39	22,554	437,322	293,614	Aug 11 04:34 PM
Cotroneo Pat	SVP, Finance and CFO	Aug 07	Sale	48.00	22,554	1,082,592	271,060	Aug 11 04:34 PM
Yu K Peony	Chief Medical Officer	Jul 24	Sale	42.35	3,351	141,915	205,576	Jul 28 07:33 PM
Cotroneo Pat	SVP, Finance and CFO	Jun 16	Sale	39.68	3,928	155,863	271,060	Jun 18 06:35 PM
Conterno Enrique A	Chief Executive Officer	Jun 11	Buy	35.28	19,800	698,599	27,800	Jun 12 06:59 AM
Conterno Enrique A	Chief Executive Officer	Jun 10	Buy	36.29	8,000	290,282	8,000	Jun 12 06:59 AM
Rosenkranz Roberto Pedro	Director	Jun 09	Option Exercise	23.85	24,000	572,400	96,100	Jun 11 09:22 PM
Chung Christine	SVP, China Operations	Mar 19	Option Exercise	25.40	7,345	186,563	166,358	Mar 19 07:55 PM
KEARNS THOMAS F JR	Director	Mar 19	Option Exercise	2.90	18,000	52,200	161,464	Mar 23 05:37 PM
KEARNS THOMAS F JR	Director	Mar 19	Sale	23.17	18,000	417,074	143,464	Mar 23 05:37 PM
Chung Christine	SVP, China Operations	Mar 19	Sale	25.91	7,345	190,282	159,013	Mar 19 07:55 PM
Chung Christine	SVP, China Operations	Mar 18	Option Exercise	25.40	400	10,160	162,918	Mar 19 07:55 PM
Chung Christine	SVP, China Operations	Mar 18	Sale	24.79	3,905	96,799	159,013	Mar 19 07:55 PM
Yu K Peony	Chief Medical Officer	Mar 16	Option Exercise	19.39	3,750	72,713	166,541	Mar 18 08:05 PM
Cotroneo Pat	SVP, Finance and CFO	Mar 16	Sale	26.36	9,239	243,540	236,466	Mar 18 08:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience